Shire is a global leader in pharmaceuticals for rare diseases, with a global turnover of 11.4 billion USD in 2016. The move is hotly debated in Japan, giving voice to Takeda becoming an international group with a reduced Japanese footprint. Other arguments are that the number of Japanese ventures iand the amount of invested funds increases, and the Japanese bio industry may be in a serious shortage of human resources.

Nikkei Biotech news release, May 8, 2018